Insider Cluster (2 insiders) ·Filed Sep 11, 2026

RLMD

RELMADA THERAPEUTICS, INC.
BULLISH
Impact 6/10
Horizonweeks Processed21d 8h ago
Insider cluster: 2 insiders, $923K total
Actionable Insight ▲ Bullish

CEO/CFO cluster buys at RLMD are the strongest insider signal in the dataset per academic literature. With the stock near $4.10-4.25 and institutional holders like Jupiter Topco ($77M) already in, this suggests management sees material upside. Monitor for upcoming pipeline catalysts or partnership announcements that could explain the concentrated buying.

DirectionBullish
Confidencehigh
Horizonweeks
Latest settled — T+5d
RLMD ▼ -8.85% at T+5d
LONG call ✗ call lost -8.85% · α vs SPY -8.63% · entry $4.52 → $4.12
Next anchor: T+20d in 7d
Latest observation: T+13 -10.01% FF3 residual α
Entry anchored
Sep 11, 07:30 AM ET
via 1-min bar
T+1d
-1.77%
call -1.77% · α -1.32%
$4.44
settled 18d ago
T+5d
-8.85%
call -8.85% · α -8.63%
$4.12
settled 14d ago
T+20d
—
call — · α —
—
in 7d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

RLMD CEO Sergio Traversa and CFO Maged Shenouda collectively purchased $1.67M of stock in open-market transactions over two days (Sep 9-10), with the CEO buying 200K shares and the CFO buying 200K shares. This is a strong cluster buy signal from both top C-suite executives, representing approximately 0.38% of the company's $434M market cap, which is a modest but notable insider conviction signal for a clinical-stage biotech.

Key Financial Metrics

Direction
buying
Total Value
$1.7M
Insiders
2

Key Facts

  • CEO Sergio Traversa purchased 200,000 shares total ($828K) on Sep 9-10 at $4.10-$4.18
  • CFO Maged Shenouda purchased 200,000 shares total ($844K) on Sep 9-10 at $4.20-$4.25
  • Combined insider purchases of $1.67M represent ~0.38% of RLMD's $434M market cap
  • Both executives bought in open-market transactions — not grants or exercises
  • Recent 30-day insider activity shows 4 buys totaling $1.7M, consistent with this cluster
  • Institutional ownership shows Jupiter Topco ($77M), BlackRock ($51M), Adage Capital ($33M) as top holders

Financial Impact

$1.67M in insider purchases, 0.38% of market cap — modest but high-signal given C-suite cluster

insider ownershipmarket confidence

Risk Factors

  • Clinical-stage biotech with no approved products — binary pipeline risk remains
  • $1.67M is only 0.38% of market cap, so signal strength depends on insider conviction rather than dollar magnitude
  • Prior neutral calls on RLMD had negative T+20 returns (-12.95%, -13.98%), suggesting the stock can be volatile on news
  • No specific catalyst disclosed — buying could be valuation-driven rather than event-driven

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RLMD-1789127045139
8 reports for RLMD
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for RLMD — sortable, filterable
TypeNow
Sep 11, 2026
21d ago
Insider Cluster
BULLISH ★ 6/10
$4.52 $4.12▼ −8.85%▼ −8.63%$3.60 (−20.35%)
May 13, 2026
20w ago
S-3ASR
BEARISH ★ 6/10
$7.42 $7.21▲ +2.83%▲ +2.11%$3.60 (+51.48%)
May 12, 2026
20w ago
8-K
NEUTRAL ★ 4/10
$7.49 $7.03▼ −6.14%▼ −4.98%$3.60 (−51.94%)
Apr 17, 2026
23w ago
DEFA14A
NEUTRAL ★ 3/10
$7.37 $7.03▼ −4.61%▼ −5.53%$3.60 (−51.15%)
Apr 3, 2026
25w ago
S-3
NEUTRAL ★ 3/10
$6.90 $7.38▲ +6.96%▲ +2.82%$3.60 (−47.83%)
Mar 19, 2026
28w ago
Press Release
BULLISH ★ 8/10
$6.07 $6.43▲ +5.93%▲ +8.08%$3.60 (−40.69%)
Mar 12, 2026
29w ago
Press Release
NEUTRAL ★ 3/10
$6.15 $6.25▲ +1.63%▲ +2.60%$3.60 (−41.46%)
Mar 9, 2026
29w ago
Press Release
NEUTRAL ★ 6/10
$7.17 $6.18▼ −13.81%▼ −12.45%$3.60 (−49.79%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Sep 11, 2026